<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[ChinaCureLink]]></title><description><![CDATA[ChinaCureLink connects international patients with leading Chinese hospitals for cancer care, CAR-T and stem cell therapy, and second opinions.]]></description><link>https://www.chinacurelink.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Fri, 30 Oct 2026 19:13:35 GMT</lastBuildDate><atom:link href="https://www.chinacurelink.com/ar/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Medical Tourism Facilitator: What They Do and How to Choose One (2026)]]></title><description><![CDATA[A medical tourism facilitator connects patients with hospitals abroad and handles records, translation and travel. This guide explains how they are paid, what a good one does before the patient flies, and which red flags mean stop.]]></description><link>https://www.chinacurelink.com/post/medical-tourism-facilitator</link><guid isPermaLink="false">6adb50548871eeb5742010e6</guid><category><![CDATA[Medical Tourism in China]]></category><pubDate>Fri, 23 Oct 2026 12:36:49 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_3114c60db2c14f408733a81b1528ce53~mv2.jpeg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[China Hospitals: How the System Works and the Best Hospitals for International Patients in 2026]]></title><description><![CDATA[Compare China hospitals for international patients: how the grading system works, top public and international hospitals by city, and how to choose one.]]></description><link>https://www.chinacurelink.com/post/china-hospitals</link><guid isPermaLink="false">6adac86b7a16f6a3ff833096</guid><category><![CDATA[Hospitals]]></category><category><![CDATA[Medical Tourism in China]]></category><pubDate>Fri, 23 Oct 2026 02:59:18 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_2b0185cea9ee488684dfd72a9f00313f~mv2.png/v1/fit/w_600,h_331,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Medical Tourism Agency in China: How to Choose a Trusted One in 2026]]></title><description><![CDATA[Medically reviewed by ChinaCureLink Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways "Medical tourism agency" covers four different services: travel agencies, medical facilitators, hospital international departments and listing directories. For serious or complex conditions, a facilitator that reviews the case first is usually the safer choice than a travel package. An agency's company, the hospital and the treating doctor can each be checked in China's official registries. The key...]]></description><link>https://www.chinacurelink.com/post/medical-tourism-agency-china</link><guid isPermaLink="false">6ad9910eed391fb73eef48a0</guid><category><![CDATA[Blog]]></category><category><![CDATA[Medical Tourism in China]]></category><pubDate>Thu, 22 Oct 2026 05:11:39 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_2e22d44e12ac431182ef9e962ce640d8~mv2.jpg/v1/fit/w_1000,h_630,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Shanghai Hospital, China: Best Hospitals for International Patients in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways Shanghai is one of China's main destinations for international patients. Its public hospitals treated 73,200 foreign patients in 2025, up more than 8% on the year before. 22 public medical institutions are official international medical tourism pilots. They include Ruijin, Zhongshan, Huashan and Renji hospitals, which are building dedicated international departments. The right hospital depends on the condition. Fudan...]]></description><link>https://www.chinacurelink.com/post/shanghai-hospital-china</link><guid isPermaLink="false">6ad5d7d10ac983b635943ce1</guid><category><![CDATA[Blog]]></category><category><![CDATA[Hospitals]]></category><pubDate>Mon, 19 Oct 2026 09:21:46 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_f15cc76cf1f14f53bb3d7cd707132f24~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Medical Insurance in China: What International Patients Need to Know in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways Visitors cannot use China's public medical insurance. It covers more than 95% of people living in China, but patients who travel there for treatment pay as self-paying patients unless their own insurance pays. Some private health plans from abroad may cover treatment in China. Insurers such as Prudential, AIA and Bupa offer plans whose cover can include China, depending on the plan and its area of cover. Cover must be...]]></description><link>https://www.chinacurelink.com/post/medical-insurance-in-china</link><guid isPermaLink="false">6ad5a3c077c2d30a8a6b1691</guid><category><![CDATA[Blog]]></category><pubDate>Mon, 19 Oct 2026 06:25:04 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_71bf4ec194574ae381697083f952c47b~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Medical Care in China: How the System Works for Foreigners in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways Medical care in China is hospital-led. Large public hospitals deliver most care, and patients can go straight to a hospital specialist without a GP referral. Visitors are not covered by China's public insurance. Foreign visitors pay out of pocket, usually upfront, and inpatient stays normally need a deposit. Going directly has limits. Patients who fly in for serious treatment without a specialist review first can face...]]></description><link>https://www.chinacurelink.com/post/medical-care-in-china</link><guid isPermaLink="false">6ad1bc089caf1d0cdb0ba3d2</guid><category><![CDATA[Blog]]></category><pubDate>Fri, 16 Oct 2026 06:25:07 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_f831701e2cc84240befbe68cf2470b5d~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[China Cures Type 1 Diabetes? Latest Stem Cell Breakthroughs (2026 Update)]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways Results are lasting: Peking University's stem cell islet results for type 1 diabetes have now lasted nearly three years (CAS, August 2026). More than one success: A Shanghai team reported three more type 1 patients in The Lancet Diabetes &#38; Endocrinology in March 2026, including a 15-year-old girl — the first child to receive this kind of therapy. Insulin-free patients: At least two Chinese type 1 patients have stopped...]]></description><link>https://www.chinacurelink.com/post/china-cures-type-1-diabetes</link><guid isPermaLink="false">6ad0f4b36074ebde81d06648</guid><category><![CDATA[News]]></category><category><![CDATA[Blog]]></category><category><![CDATA[Diabetes]]></category><pubDate>Thu, 15 Oct 2026 16:02:13 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_7f4c7ae9674342b3957eda2d07c639f5~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[The Best Hospitals in Beijing, China: International Patients Guide in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways Beijing has China's deepest bench of top hospitals. Peking Union Medical College Hospital has topped Fudan University's national hospital ranking for more than a decade. Foreign-friendly care is now widespread. Beijing has 52 medical institutions with international departments, 156 offering full foreign-language service and 167 accepting international bank cards. The right hospital depends on the condition. Fuwai...]]></description><link>https://www.chinacurelink.com/post/beijing-hospital-china</link><guid isPermaLink="false">6ad0d8b2e1e8e23672f08d7f</guid><category><![CDATA[Blog]]></category><pubDate>Thu, 15 Oct 2026 14:16:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_948e1314a9c840f5bc9dcb8e9a7989b9~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[China Medical Tourism in 2026: A Patient's Guide to Costs, Visas, Hospitals and Risks]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways China medical tourism is growing fast. Major Chinese hospitals recorded about 1.28 million international patient visits in 2025, up 73.6% in three years, and patients from Europe and North America doubled. Some treatments are hard to get anywhere else. China approved the world's first CAR-T for a solid tumour in 2026, and the Boao Lecheng pilot zone in Hainan offers drugs approved abroad but not yet in mainland China....]]></description><link>https://www.chinacurelink.com/post/china-medical-tourism</link><guid isPermaLink="false">6ad069e15510cf48b692dbf4</guid><category><![CDATA[Advances]]></category><category><![CDATA[Blog]]></category><pubDate>Thu, 15 Oct 2026 06:26:43 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_a9d4585e1b0a4762a557a84ede3f73d5~mv2.png/v1/fit/w_1000,h_941,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Did China Find a Cancer Cure? Approved Treatments, Trials and Access for International Patients in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways China has not found one cure for every cancer, but it is turning breakthroughs into approved treatments at record pace. Between 2020 and 2025 it approved 94 new cancer drugs, more than the US FDA's 87. World first for solid tumours. In June 2026 China approved satri-cel, the first CAR-T cell therapy for any solid tumour, for advanced Claudin18.2-positive stomach cancer. A new lung cancer standard. Ivonescimab, a...]]></description><link>https://www.chinacurelink.com/post/cancer-cure-china</link><guid isPermaLink="false">6ad04809d49d5d21e2c8e771</guid><category><![CDATA[Advances]]></category><category><![CDATA[Blog]]></category><pubDate>Thu, 15 Oct 2026 04:36:29 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_ed11b92b5844428e837e7f1c72b47657~mv2.png/v1/fit/w_1000,h_941,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[China Cancer Vaccine 2026: Approved Options, Trials, Eligibility and Access]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways China already offers two personalised dendritic cell (DC) cancer vaccines in the Boao Lecheng pilot zone in Hainan: Neo-DCAct™ at West China Lecheng Hospital for a wide range of solid tumours, and Germany's LANEX-DC® at Boao Super Hospital for advanced pancreatic and colorectal cancer. In pancreatic cancer patients treated after surgery, LANEX-DC® was linked to a median overall survival of 29.4 months, with 39.3% of...]]></description><link>https://www.chinacurelink.com/post/china-cancer-vaccine</link><guid isPermaLink="false">6acfa30af01b30c0f5055e9b</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Wed, 14 Oct 2026 16:04:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_a77864715efd49fc8f64396db830bd32~mv2.png/v1/fit/w_1000,h_941,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Did China Cure Diabetes? Approved Treatments, Trials, Eligibility and Access for International Patients in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang, Medical Editor, ChinaCureLink Key Takeaways China has moved diabetes beyond lifelong management. Chinese doctors have freed type 1 and type 2 patients from insulin, with the longest reported result lasting more than 33 months. Type 2 stem cell therapy is already approved. In January 2026, Hainan's Boao Lecheng pilot zone approved umbilical cord mesenchymal stem cell (UC-MSC) therapy for type 2 diabetes, with a published price, and has already treated an...]]></description><link>https://www.chinacurelink.com/post/china-cure-diabetes</link><guid isPermaLink="false">6acf8cda160622016bf4ce09</guid><category><![CDATA[Blog]]></category><category><![CDATA[Stem Cell]]></category><pubDate>Wed, 14 Oct 2026 15:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_a6a7826901f3408f9867d56458604f06~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Satri-cel vs Chemotherapy for Advanced Gastric Cancer (2026)]]></title><description><![CDATA[Medically reviewed by Dr. Wang Key Takeaways Treatment: Satricabtagene autoleucel (satri-cel), a chimeric antigen receptor T-cell (CAR-T) therapy targeting claudin-18 isoform 2 (CLDN18.2). Condition: Selected patients with advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, a cancer arising in the stomach or where it meets the oesophagus. Availability in China: Approved in China for a defined indication. Approval does not confirm an individual treatment place. Location:...]]></description><link>https://www.chinacurelink.com/post/satri-cel-vs-chemotherapy-gastric-cancer</link><guid isPermaLink="false">6acd2c7a5971729ecdad8315</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Tue, 13 Oct 2026 19:15:06 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_678d747f1aff4409b458f11a50e81181~mv2.jpeg/v1/fit/w_1000,h_896,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Recurrent Stomach Cancer: 5 Treatment Options in 2026]]></title><description><![CDATA[Medically reviewed by Dr. Wang Key Takeaways Treatment: Five discussion pathways: chemotherapy with targeted therapy, HER2-targeted treatment, immunotherapy, CLDN18.2-targeted treatment and clinical trials. Condition: Recurrent gastric adenocarcinoma; other stomach tumour types need different treatment pathways. Availability in China: Satri-cel has a defined Chinese approval reported by a government source; approval is separate from individual eligibility and access. Location: Begin with your...]]></description><link>https://www.chinacurelink.com/post/recurrent-stomach-cancer-treatment</link><guid isPermaLink="false">6ace54543885875dd25eb30a</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><category><![CDATA[CAR-T]]></category><pubDate>Tue, 13 Oct 2026 19:10:06 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_8626832cee9e4fdcbca8e1c8e1bda616~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[CAR-T for Solid Tumors in 2026: What Is Approved and What Is Still a Trial]]></title><description><![CDATA[Medically reviewed by Dr. Wang Key Takeaways Treatment: CAR-T engineers T cells to recognize a target on cancer cells; TIL and TCR-T are different cell-therapy approaches. Condition: Solid tumours are a broad group; evidence and approvals apply to particular diagnoses and targets. Availability in China: Satri-cel approval is reported for a defined CLDN18.2-positive, HER2-negative advanced gastric/GEJ cancer population after previous treatment. Location: Approval is jurisdiction-specific;...]]></description><link>https://www.chinacurelink.com/post/car-t-for-solid-tumors</link><guid isPermaLink="false">6ace61b0a69f56b914139a19</guid><category><![CDATA[Blog]]></category><category><![CDATA[CAR-T]]></category><category><![CDATA[Advances]]></category><pubDate>Tue, 13 Oct 2026 19:02:33 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_6a8ddfb1acef4a4ab4f706560df92436~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Satri-cel China 2026: Step-by-Step Application for International Patients]]></title><description><![CDATA[Medically reviewed by Dr . Wang Key Takeaways Treatment: Satricabtagene autoleucel (satri-cel/CT041), a chimeric antigen receptor T-cell (CAR-T) therapy made from the patient’s own immune cells. Condition: Advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Availability in China: China’s National Medical Products Administration (NMPA) announced approval on 22 June 2026; individual hospital acceptance must be confirmed. Location: A Chinese centre with current satri-cel...]]></description><link>https://www.chinacurelink.com/post/satri-cel-china-application-international-patients</link><guid isPermaLink="false">6ac92f59d3466ffa9b968791</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Sat, 10 Oct 2026 13:43:36 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_9bbb940224d24096af2a9bc492b3341a~mv2.jpeg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[CLDN18.2 Stomach Cancer 2026: What a Positive Result Means]]></title><description><![CDATA[Medically reviewed by Dr . Wang Key Takeaways Treatment: CLDN18.2-targeted options include the antibody zolbetuximab and satricabtagene autoleucel, or satri-cel, a chimeric antigen receptor T-cell (CAR-T) therapy. They are different treatments. Condition: The treatment indications discussed here concern advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, a gland-forming cancer of the stomach or the area where it meets the oesophagus. Availability in China: China’s National...]]></description><link>https://www.chinacurelink.com/post/cldn18-2-stomach-cancer-positive-meaning</link><guid isPermaLink="false">6ac9399b86e1da51f6fcdec0</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Sat, 10 Oct 2026 13:39:58 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_9b22ed41f4dd4378b79a1e023d37eabb~mv2.jpeg/v1/fit/w_1000,h_900,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[CAR-T for Stomach Cancer in China: International Patient Guide (2026)]]></title><description><![CDATA[Medically reviewed by  Dr. Wang Key Takeaways Treatment: Satricabtagene autoleucel, called satri-cel or CT041, uses the patient’s own modified immune cells to target claudin-18 isoform 2 (CLDN18.2). Condition: Advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, a cancer of the stomach or the area where it meets the food pipe. Availability in China: Approved for a defined indication; the receiving hospital must confirm acceptance. Location: A specialist centre with verified...]]></description><link>https://www.chinacurelink.com/post/car-t-stomach-cancer-china-international-patients</link><guid isPermaLink="false">6ac924ce75cf17ffe4e2faf6</guid><category><![CDATA[Blog]]></category><category><![CDATA[CAR-T]]></category><category><![CDATA[Advances]]></category><pubDate>Sat, 10 Oct 2026 13:30:04 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_9018b5560fc344a58b2e85694d135c56~mv2.jpeg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Travelling to China for Medical Treatment: What International Patients Need in 2026]]></title><description><![CDATA[Medically reviewed by  Dr . Wang Key Takeaways What should we arrange before travelling to China? Treatment: Case-specific specialist care following medical review. Condition: Serious or complex conditions requiring diagnosis-specific assessment. Availability in China: Depends on the treatment, hospital and individual case; acceptance must be confirmed. Location: Mainland China; choose the destination after identifying an appropriate hospital. Estimated cost: Obtain an individual written...]]></description><link>https://www.chinacurelink.com/post/how-to-travel-to-china-for-medical-treatment-2026</link><guid isPermaLink="false">6ac7c704eb795dcefd0f14da</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Thu, 08 Oct 2026 19:27:33 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_d8a44a898ee94dabb03faca65a5c189a~mv2.jpeg/v1/fit/w_1000,h_896,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item><item><title><![CDATA[Which Hospital in China Is Right for Me? How ChinaCureLink Matches Your Case]]></title><description><![CDATA[Medically reviewed by Dr . Wang Key Takeaways How does ChinaCureLink match my case? Treatment: Hospital matching and care coordination; the receiving medical team recommends treatment. Condition: Serious diseases requiring specialist assessment; suitability depends on the individual case. Availability in China: Depends on the hospital's review and availability of the proposed service. Location: The city and provider follow the case assessment. Estimated cost: A case-specific quotation is...]]></description><link>https://www.chinacurelink.com/post/chinacurelink-hospital-matching</link><guid isPermaLink="false">6ac7d17b41629e9f0c9e8fc2</guid><category><![CDATA[Blog]]></category><category><![CDATA[Advances]]></category><pubDate>Thu, 08 Oct 2026 19:17:06 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_f3972792f30e480e8e4e6dda9c365c1a~mv2.jpeg/v1/fit/w_1000,h_896,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>ChinaCureLink</dc:creator></item></channel></rss>